Loading
A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide is a phase 2 interventional study registered as NCT02815033 by The European Uro-Oncology Group, with 66 participants recorded, started 2015-07 and reaching its primary completion in 2020-06. Interventions recorded: Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI, Bone scan. Conditions recorded: Prostate Cancer Metastatic.
Linked to the technology Whole-body MRI because the registry names it ("whole body mri") among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Whole-body MRI, Enzalutamide, Prostate cancer and the tag pipeline.
Shares Whole-body MRI, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.